Belite Bio (BLTE) to Release Quarterly Earnings on Monday

Belite Bio (NASDAQ:BLTE) will likely be issuing its quarterly earnings data before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter.

Belite Bio Stock Performance

Shares of BLTE opened at $63.19 on Friday. The stock has a market capitalization of $2.01 billion, a PE ratio of -56.93 and a beta of -1.54. Belite Bio has a 1 year low of $31.00 and a 1 year high of $86.53. The company’s 50-day simple moving average is $57.86 and its 200-day simple moving average is $59.57.

Analysts Set New Price Targets

BLTE has been the topic of several research reports. Maxim Group increased their price target on shares of Belite Bio from $60.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. HC Wainwright upped their target price on shares of Belite Bio from $60.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Benchmark upped their target price on shares of Belite Bio from $57.00 to $79.00 and gave the stock a “buy” rating in a research note on Tuesday, January 21st.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.